To explore the efficacy and toxicity of an extended schedule of temozolomide (50 mg/mq 1 week on/1 week off) in a population of newly diagnosed low-grade gliomas (LGG).
Methods
Primary endpoints were progression-free survival (PFS) at 12 and 24 months and response rate evaluated with Response Assessment in Neuro-Oncology Criteria. Secondary endpoints were clinical benefit (reduction of seizures frequency), reduction of steroid, and modifications of Karnofsky Performance Status.
Results
From 2006 to 2009, we enrolled 14 consecutive patients with newly diagnosed LGG: 8 grade II astrocytomas, 2 oligodendroglioma, and 4 oligo-astrocytoma. Temozolomide was administered for 18 cycles (mean) per patient (range 3-24 cycles). In 57.5% (n = 8), we observed stable disease, 28.5% (n = 4) presented a minor response, and 14% (n = 2) showed progression. Five patients presented early progression during the first year of treatment and the study was stopped. A relevant clinical benefit was observed in 85% of patients (seizure control). After 6 years of follow-up, only 4 patients died. Prolonged PFS was associated with 1p-19q codeletion over 1p-19q intact (35 vs 4 months; p<0.04) and IDH1 mutation over IDH1 wild-type (36 vs 6 months; p<0.009).
Conclusions
The study was interrupted for the high rate of progression observed in the first 14 patients enrolled. However, our results show that an extended low dose of temozolomide presents interesting activity with objective response and clinical benefit, but does not seem to prevent progression in patients presenting unfavorable molecular prognostic factors.
Get full access to this article
View all access options for this article.
References
1.
Central Brain tumor registry of the United States: Statistical report: Primary brain tumors in the United States, 2000-2004, Available at http://www.cbts.org/reports//2007-2008/2007 reportpdf. Accessed: February 2010.
2.
SoffiettiRBaumertBGBelloLet al;European Federation of Neurological Societies. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol. 2010;17 (9):1124–1133.
SchiffDBrownPDGianniniCOutcome in adult low-grade glioma: the impact of prognostic factors and treatment. Neurology. 2007;69 (13):1366–1373.
5.
PignattiFvan den BentMCurranDet al;European Organization for Research and Treatment of Cancer Radiotherapy Cooperative Group. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002;20 (8):2076–2084.
6.
PetersonKDeAngelisLMWeighing the benefits and risks of radiation therapy for low-grade glioma. Neurology. 2001;56 (10):1255–1256.
7.
PostmaTJKleinMVerstappenCCPRadiotherapy-induced cerebral abnormalities in patients with low-grade glioma. Neurology. 2002;59 (1):121–123.
8.
Surma-ahoONiemeläMVilkkiJAdverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology. 2001;56 (10):1285–1290.
9.
PackerRJMehtaMNeurocognitive sequelae of cancer treatment. Neurology. 2002;59 (1):8–10.
10.
TaphoornMJSchiphorstAKSnoekFJCognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy. Ann Neurol. 1994;36 (1):48–54.
11.
KarimABMFAfraDCornuPRandomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys. 2002;52 (2):316–324.
12.
PackerRJAterJAllenJCarboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg. 1997;86 (5):747–754.
13.
MassiminoMSpreaficoFCefaloGHigh response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J Clin Oncol. 2002;20 (20):4209–4216.
14.
PradosMDEdwardsMSBRabbittJLambornKDavisRLLevinVATreatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. J Neurooncol. 1997;32 (3):235–241.
15.
GlassJHochbergFHGruberMLLouisDNSmithDRattnerBThe treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg. 1992;76 (5):741–745.
16.
BaumertBGMasonWPRyanGTemozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss) low-grade glioma: a randomized phase III intergroup study by the EORTC/ NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033). J Clin Oncol. 2013(suppl; abstr 2007).
17.
SoffiettiRRudàRBradacGBSchifferDPCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery. 1998;43 (5):1066–1073.
18.
MasonWPKrolGSDeAngelisLMLow-grade oligodendroglioma responds to chemotherapy. Neurology. 1996;46 (1):203–207.
19.
BucknerJCGesmeDJrO'FallonJRPhase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol. 2003;21 (2):251–255.
20.
ViviersLBradaMA phase II trial of primary chemotherapy with Temozolomide in patients with low-grade cerebral gliomas. Neuro-Oncology July. 2000;2 (Suppl 1):S43(abstr 264).
21.
BradaMViviersLAbsonCPhase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol. 2003;14 (12):1715–1721.
22.
PaceAVidiriAGalièETemozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol. 2003;14 (12):1722–1726.
23.
BrockCSNewlandsESWedgeSRPhase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 1998;58 (19):4363–4367.
24.
KhanRBRaizerJJMalkinMGBazylewiczKAAbreyLEA phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro-oncol. 2002;4 (1):39–43.
25.
KesariSSchiffDDrappatzJPhase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res. 2009;15 (1):330–337.
26.
KoekkoekJAKerkhofMDirvenLHeimansJJReijneveldJCTaphoornMJSeizure outcome after radiotherapy and chemotherapy in low-grade glioma patients: a systematic review. Neuro-oncol. 2015;17 (7):924–934.
27.
CairncrossJGUnderstanding low-grade glioma: a decade of progress. Neurology. 2000;54 (7):1402–1403.
28.
BucknerJCShawEGPughSLRadiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med. 2016;374 (14):1344–1355.
29.
CairncrossJGUekiKZlatescuMCSpecific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90 (19):1473–1479.
30.
CianciulliAMMoraceEColettaAMInvestigation of genetic alterations associated with development and adverse outcome in patients with astrocytic tumor. J Neurooncol. 2000;48 (2):95–101.
31.
TadaKShiraishiSKamiryoTAnalysis of loss of heterozygosity on chromosome 10 in patients with malignant astrocytic tumors: correlation with patient age and survival. J Neurosurg. 2001;95 (4):651–659.
32.
SmithJSPerryABorellTJAlterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol. 2000;18 (3):636–645.
33.
WatanabeTNakamuraMKrosJMPhenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathol. 2002;103 (3):267–275.
34.
KaloshiGBenouaich-AmielADiakiteFTemozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology. 2007;68 (21):1831–1836.
35.
MetellusPCoulibalyBColinCAbsence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol. 2010;120 (6):719–729.
36.
DubbinkHJTaalWvan MarionRIDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology. 2009;73 (21):1792–1795.
37.
WenPYMacdonaldDRReardonDAUpdated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28 (11):1963–1972.
38.
WieserHGBlumeWTFishDet al;Commission on Neurosurgery of the International League Against Epilepsy (ILAE). ILAE Commission Report. Proposal for a new classification of outcome with respect to epileptic seizures following epilepsy surgery. Epilepsia. 2001;42 (2):282–286.
39.
A'HernRP. Sample size tables for exact single-stage phase II designsm. Stat Med. 2001;20:859–866.
40.
KleinMEngelbertsNHvan der PloegHMEpilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann Neurol. 2003;54 (4):514–520.
41.
TaphoornMJKleinMCognitive deficits in adult patients with brain tumours. Lancet Neurol. 2004;3 (3):159–168.
42.
AaronsonNKTaphoornMJHeimansJJCompromised health-related quality of life in patients with low-grade glioma. J Clin Oncol. 2011;29 (33):4430–4435.
43.
de GrootMReijneveldJCAronicaEHeimansJJEpilepsy in patients with a brain tumour: focal epilepsy requires focused treatment. Brain. 2012;135 (Pt 4):1002–1016.
44.
CiceroniCBonelliMMastrantoniEType-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas. Cell Death Differ. 2013;20 (3):396–407.
45.
LittermanAJZellmerDMGrinnenKLProfound impairment of adaptive immune responses by alkylating chemotherapy. J Immunol. 2013;190 (12):6259–6268.
46.
ShamjiMFFric-ShamjiECBenoitBGBrain tumors and epilepsy: pathophysiology of peritumoral changes. Neurosurg Rev. 2009;32 (3):275–284, discussion 284-286.
47.
van den BentMJChemotherapy for low-grade glioma: when, for whom, which regimen?Curr Opin Neurol. 2015;28 (6):633–938.
